---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-188839"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2023-07-18T23:59:59+00:00"
generated_at: "2026-06-13T06:48:32.844904+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acadia expands trofinetide rights globally; Q2 DAYBUE net sales $21-23M

## Summary
- Acadia pays Neuren $100M upfront for ex-North American trofinetide rights and global NNZ-2591 rights in Rett/Fragile X.
- Potential milestone payments up to $405M each for trofinetide and NNZ-2591 in North America; additional milestones outside NA.
- Preliminary Q2 2023 DAYBUE net sales $21-23M; Q3 guidance $45-55M.
- NUPLAZID Q2 preliminary net sales $140-144M; full year 2023 guidance $530-545M.
- Acadia to submit NDS for trofinetide in Canada within 18 months; plans for Europe, Asia later.

## SEC filing metadata
- accession: 0001193125-23-188839
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2023-07-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312523188839/0001193125-23-188839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312523188839/d533087d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-188839
- JSON: https://secwatch.observer/filing/0001193125-23-188839.json
- Plain text: https://secwatch.observer/filing/0001193125-23-188839.txt

## Key facts
- Earnings Releases
  ACADIA PHARMACEUTICALS INC reported second quarter of 2023 results: revenue $140 to $144 million. Guidance reaffirmed.
  - Period: second quarter of 2023
  - Revenue: $140 to $144 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: DAYBUE 2Q 2023 preliminary net sales: $21 to $23 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000119312523188839/0001193125-23-188839-index.htm
- Earnings Releases
  ACADIA PHARMACEUTICALS INC reported second quarter of 2023 results: revenue $140 to $144 million. Guidance reaffirmed.
  - Period: second quarter of 2023
  - Revenue: $140 to $144 million
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: NUPLAZID 2Q 2023 preliminary net sales: $140 to $144 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000119312523188839/0001193125-23-188839-index.htm
- Material Agreements
  ACADIA PHARMACEUTICALS INC entered into Joint Venture and License Agreement with Neuren Pharmaceuticals Limited valued at upfront payment $100.0 million; milestone payments up to $405.0 million per product; tiered double-d (effective 2023-07-13).
  - Action: entry
  - Agreement: license
  - Counterparty: Neuren Pharmaceuticals Limited
  - Value: upfront payment $100.0 million; milestone payments up to $405.0 million per product; tiered double-d
  - Effective: 2023-07-13
  source text: On July 13, 2023, Acadia Pharmaceuticals Inc. (the “Company”) and Neuren Pharmaceuticals Limited (“Neuren”) entered into a joint venture and license agreement (the “License Agreement”) for the global commercialization and development of trofinetide and of Neuren’s development candidate NNZ-2591.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070494/000119312523188839/0001193125-23-188839-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.